{"id":14414,"date":"2020-01-15T09:30:03","date_gmt":"2020-01-15T08:30:03","guid":{"rendered":"https:\/\/asscat-hepatitis.org\/?p=14414"},"modified":"2020-01-15T09:30:03","modified_gmt":"2020-01-15T08:30:03","slug":"les-dones-que-pateixen-la-sindrome-dovari-poliquistic-presenten-amb-major-frequencia-nash-esteatohepatitis-no-alcoholica-amb-fibrosi-hepatica-avancada","status":"publish","type":"post","link":"https:\/\/asscat-hepatitis.org\/ca\/les-dones-que-pateixen-la-sindrome-dovari-poliquistic-presenten-amb-major-frequencia-nash-esteatohepatitis-no-alcoholica-amb-fibrosi-hepatica-avancada\/","title":{"rendered":"Les dones que pateixen la s\u00edndrome d\u2019ovari poliqu\u00edstic presenten amb major freq\u00fc\u00e8ncia NASH (esteatohepatitis no alcoh\u00f2lica) amb fibrosi hep\u00e0tica avan\u00e7ada"},"content":{"rendered":"<p>[et_pb_section bb_built=&#8221;1&#8243; disabled_on=&#8221;off|off|off&#8221; _builder_version=&#8221;3.0.106&#8243; custom_margin=&#8221;|||&#8221; custom_padding=&#8221;0px||0px|&#8221; next_background_color=&#8221;#000000&#8243;][et_pb_row custom_padding=&#8221;0px||0px|&#8221; _builder_version=&#8221;3.0.106&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_post_title author=&#8221;off&#8221; date_format=&#8221;d\/m\/Y&#8221; comments=&#8221;off&#8221; featured_placement=&#8221;background&#8221; text_background=&#8221;on&#8221; text_bg_color=&#8221;#ffffff&#8221; module_class=&#8221;ac-post-title-section-0&#8243; _builder_version=&#8221;3.0.106&#8243; title_font=&#8221;Montserrat|600|||||||&#8221; title_text_color=&#8221;#2d2d2d&#8221; title_letter_spacing=&#8221;-1px&#8221; title_line_height=&#8221;1.2em&#8221; meta_font=&#8221;Open Sans||||||||&#8221; meta_text_color=&#8221;rgba(45,45,45,0.5)&#8221; text_orientation=&#8221;center&#8221; custom_margin=&#8221;|||&#8221; custom_padding=&#8221;|20px|20px|20px&#8221; title_text_align=&#8221;center&#8221; meta_font_size=&#8221;13px&#8221; meta_text_align=&#8221;center&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_post_title][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section bb_built=&#8221;1&#8243; specialty=&#8221;on&#8221; _builder_version=&#8221;3.0.106&#8243; custom_padding=&#8221;0px|||&#8221; prev_background_color=&#8221;#000000&#8243; next_background_color=&#8221;#000000&#8243;][et_pb_column type=&#8221;2_3&#8243; specialty_columns=&#8221;2&#8243;][et_pb_row_inner admin_label=&#8221;Fila&#8221; _builder_version=&#8221;3.0.106&#8243;][et_pb_column_inner type=&#8221;4_4&#8243; saved_specialty_column_type=&#8221;2_3&#8243;][et_pb_text admin_label=&#8221;Contenido Entrada 1&#8243; ul_type=&#8221;square&#8221; module_class=&#8221;ac-posts-content&#8221; _builder_version=&#8221;3.0.106&#8243; text_orientation=&#8221;justified&#8221; background_layout=&#8221;light&#8221;]<\/p>\n<h3>Introducci\u00f3<\/h3>\n<p>La s\u00edndrome d\u2019ovari poliqu\u00edstic \u00e9s una malaltia endocrina relativament comuna que afecta aproximadament al 10% de les dones en edat reproductiva. La majoria de les dones amb ovari poliqu\u00edstic tenen resist\u00e8ncia a la insulina i nivells alts de testosterona. Tamb\u00e9 s\u00f3n relativament freq\u00fcents en aquestes dones, la dislip\u00e8mia i l\u2019obesitat.<\/p>\n<p>Les alteracions hormonals i metab\u00f2liques es presenten juntament amb la malaltia del fetge gras no alcoh\u00f2lic (NAFLD), que t\u00e9 lloc en el 40-50% de les dones amb ovari poliqu\u00edstic i actualment es reconeix com un grup de risc per a NAFLD\/NASH.<\/p>\n<p>No est\u00e0 clar si la s\u00edndrome d\u2019ovari poliqu\u00edstic tamb\u00e9 est\u00e0 associat amb manifestacions cl\u00ednicament m\u00e9s avan\u00e7ades de NAFLD, com l\u2019esteatohepatitis no alcoh\u00f2lica (NASH) i la fibrosi associada a NASH. Per tant, l\u2019objectiu de l\u2019estudi va ser avaluar si la s\u00edndrome d\u2019ovari poliqu\u00edstic s\u2019associava amb una lesi\u00f3 hep\u00e0tica associada a la NAFLD m\u00e9s greu en comparaci\u00f3 amb les dones en edat reproductiva sense la s\u00edndrome d\u2019ovari poliqu\u00edstic. Pel que s\u2019aconsella que al diagnosticar s\u00edndrome d\u2019ovari poliqu\u00edstic es realitz\u00e9s una ecografia abdominal i a la inversa, o sigui s\u2019hauria de sospitar s\u00edndrome d\u2019ovari poliqu\u00edstic en dones joves que presenten NAFLD, aix\u00ed com avaluar la malaltia hep\u00e0tica que podria ser m\u00e9s greu en aquesta poblaci\u00f3 jove. Aquests descobriments tamb\u00e9 donarien suport als esfor\u00e7os per avaluar els tractaments de NASH en aquest grup de risc diferent hormonal i metab\u00f2licament.<\/p>\n<h3>Resum<\/h3>\n<p>La s\u00edndrome d\u2019ovari poliqu\u00edstic afecta al 10% de les dones en edat reproductiva i est\u00e0 marcat per menstruacions irregulars i andr\u00f2gens alts. \u00c9s un factor de risc conegut per a l\u2019esteatosi hep\u00e0tica confirmada per imatge, i l\u2019objectiu va ser avaluar si la s\u00edndrome d\u2019ovari poliqu\u00edstic influ\u00efa en la gravetat histol\u00f2gica de la malaltia del fetge gras no alcoh\u00f2lic.<\/p>\n<h3>M\u00e8todes<\/h3>\n<p>Estudi retrospectiu de dones de 18 a 45 anys amb NAFLD confirmat per bi\u00f2psia hep\u00e0tica entre els anys 2008-2019. Es va recollir si tenien comorbiditats metab\u00f2liques. Les caracter\u00edstiques histol\u00f2giques de l\u2019esteatohepatitis no alcoh\u00f2lica (NASH, en les seves sigles en angl\u00e8s) van ser avaluades independentment per dos pat\u00f2legs que desconeixien el diagn\u00f2stic de s\u00edndrome d\u2019ovari poliqu\u00edstic.<\/p>\n<h3>Resultats<\/h3>\n<p>Entre 102 dones que complien els criteris de l\u2019estudi, 36% (n = 37) tenien s\u00edndrome d\u2019ovari poliqu\u00edstic; la mitjana d\u2019edat va ser de 35 anys. Les dones amb s\u00edndrome d\u2019ovari poliqu\u00edstic tenien elevaci\u00f3 de colesterol LDL (123 vs. 101 mg\/dL, p = 0,02), aix\u00ed com de l\u2019IMC (38 vs. 33 kg\/cm<sup>2<\/sup>, p &lt;0,01). NASH va estar present en el 76% de les dones amb s\u00edndrome d\u2019ovari poliqu\u00edstic vs. 66% sense s\u00edndrome d\u2019ovari poliqu\u00edstic (p = 0,3), i les pacients amb s\u00edndrome d\u2019ovari poliqu\u00edstic van tenir en major proporci\u00f3 balonitzaci\u00f3 dels hepat\u00f2cits (32 vs. 13%, p = 0,02), i pres\u00e8ncia de fibrosi lleu (84 vs. 66%, p = 0,06) i fibrosi avan\u00e7ada (16 vs. 6%, p = 0,10). Ajustat per edat i IMC, la s\u00edndrome d\u2019ovari poliqu\u00edstic es va mantenir associat amb balonitzaci\u00f3 dels hepat\u00f2cits (OR 3,4, IC 95% 1,1-10,6, p = 0,03) i fibrosi avan\u00e7ada (OR 7,1, IC 95% 1,3- 39, p = 0,02). Entre les dones amb fibrosi avan\u00e7ada, la mitjana d\u2019edat va ser 5 anys menor en aquelles amb s\u00edndrome d\u2019ovari poliqu\u00edstic (40 enfront a 45 anys, p = 0,02).<\/p>\n<h3>Conclusi\u00f3<\/h3>\n<p>La s\u00edndrome d\u2019ovari poliqu\u00edstic s\u2019associa independentment amb NASH m\u00e9s greu, inclosa la fibrosi avan\u00e7ada.<\/p>\n<p>&nbsp;<\/p>\n<p>Refer\u00e8ncia: Liver Int. 2019 Oct 18. doi: 10.1111\/LIV.14279<\/p>\n<p>Article tradu\u00eft i adaptat per l\u2019ASSCAT<\/p>\n<p>[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=&#8221;Fila&#8221; custom_padding=&#8221;0px|||&#8221; _builder_version=&#8221;3.0.105&#8243; custom_margin=&#8221;|||&#8221;][et_pb_column_inner type=&#8221;4_4&#8243; saved_specialty_column_type=&#8221;2_3&#8243;][et_pb_post_title admin_label=&#8221;Metadatos &#8211; Fecha \u00daltima actualizaci\u00f3n&#8221; title=&#8221;off&#8221; author=&#8221;off&#8221; date_format=&#8221;d\/m\/Y&#8221; categories=&#8221;off&#8221; comments=&#8221;off&#8221; featured_image=&#8221;off&#8221; _builder_version=&#8221;3.0.106&#8243; title_text_align=&#8221;left&#8221; meta_font=&#8221;Open Sans||||||||&#8221; meta_text_align=&#8221;left&#8221; meta_font_size=&#8221;13px&#8221; meta_text_color=&#8221;#0082ca&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#cccccc&#8221; custom_margin=&#8221;50px|||&#8221; custom_padding=&#8221;10px|||&#8221; custom_css_before=&#8221;content:%22\u00daltima actualizaci\u00f3n:%22;&#8221; global_module=&#8221;3449&#8243; saved_tabs=&#8221;all&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_post_title][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243;][et_pb_sidebar orientation=&#8221;right&#8221; area=&#8221;et_pb_widget_area_8&#8243; module_class=&#8221;ac-posts-sidebar&#8221; _builder_version=&#8221;3.0.106&#8243; global_module=&#8221;3198&#8243; saved_tabs=&#8221;all&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_sidebar][\/et_pb_column][\/et_pb_section][et_pb_section bb_built=&#8221;1&#8243; _builder_version=&#8221;3.0.106&#8243; custom_padding=&#8221;||0px|&#8221; prev_background_color=&#8221;#000000&#8243; module_class=&#8221;ac-post-section-share-rrss&#8221;][et_pb_row custom_padding=&#8221;||0px|&#8221; custom_margin=&#8221;|||&#8221; _builder_version=&#8221;3.0.105&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_divider color=&#8221;#e20611&#8243; show_divider=&#8221;on&#8221; divider_style=&#8221;ridge&#8221; _builder_version=&#8221;3.0.106&#8243; \/][et_pb_text _builder_version=&#8221;3.0.106&#8243; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#e20611&#8243; text_orientation=&#8221;center&#8221; custom_margin=&#8221;||0px|&#8221; custom_padding=&#8221;|||&#8221; background_layout=&#8221;light&#8221; disabled=&#8221;on&#8221;]<\/p>\n<h5>Desde aqu\u00ed puedes compartir esta publicaci\u00f3n. \u00a1Gracias!<\/h5>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n<!-- Begin Yuzo --><div class='yuzo_related_post style-1'  data-version='5.12.77'><!-- without result --><div class='yuzo_clearfixed yuzo__title yuzo__title'><h3>Related Post<\/h3><\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/les-farmaceutiques-a-espanya-participen-ja-en-mes-de-30-assajos-clinics-enfront-a-covid-19\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/farmas-150x150.jpg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">Les farmac\u00e8utiques a Espanya participen ja en m\u00e9s ...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/revista-digital-asscatinform-numero-15-2\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/asscatinforma-15-150x150.jpg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">Revista digital asscatinform@ n\u00famero 15<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/el-consum-de-cocaina-deterioraria-la-funcio-dels-ronyons-en-persones-coinfectades-per-vih-i-hepatitis-c\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/cocaina-150x150.jpeg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">El consum de coca\u00efna deterioraria la funci\u00f3 dels r...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/labordatge-integral-dels-focus-primaris-de-la-infeccio-pel-vhc-una-de-les-claus-en-el-control-de-lhepatitis-c-a-espanya\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/javier-crespo-150x150.jpeg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">L\u2019abordatge integral dels focus primaris de la inf...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n<\/div> <style>\n\t\t\t\t\t\t\t\t.yuzo_related_post img{width:120px !important; height:110px !important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb{line-height:15px;background: !important;color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover{background:#fcfcf4 !important; -webkit-transition: background 0.2s linear; -moz-transition: background 0.2s linear; -o-transition: background 0.2s linear; transition: background 0.2s linear;;color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb a{color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb a:hover{ color:}!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover a{ color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .yuzo_text {color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover .yuzo_text {color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb{  margin: 0px  0px  0px  0px;   padding: 5px  5px  5px  5px;  }\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/style> <script>\n\t\t\t\t\t\t  jQuery(document).ready(function( $ ){\n\t\t\t\t\t\t\t\/\/jQuery('.yuzo_related_post').equalizer({ overflow : 'relatedthumb' });\n\t\t\t\t\t\t\tjQuery('.yuzo_related_post .yuzo_wraps').equalizer({ columns : '> div' });\n\t\t\t\t\t\t   })\n\t\t\t\t\t\t  <\/script> <!-- End Yuzo :) -->","protected":false},"excerpt":{"rendered":"<p>Les alteracions hormonals i metab\u00f2liques es presenten juntament amb la malaltia del fetge gras no alcoh\u00f2lic (NAFLD), que t\u00e9 lloc en el 40-50% de les dones amb ovari poliqu\u00edstic i actualment es reconeix com un grup de risc per a NAFLD\/NASH.<\/p>\n","protected":false},"author":9,"featured_media":14417,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_crdt_document":"","footnotes":""},"categories":[567,568],"tags":[5250,1760,4128,5253,1302,5251,1286,726,4060,5252],"class_list":["post-14414","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articulos-ca","category-articulos-cientificos-ca","tag-alteracions-hormonals","tag-alteracions-metaboliques","tag-articles-cientifics-ca","tag-dones-ca","tag-fibrosi-hepatica-avancada","tag-grup-de-risc","tag-investigacio","tag-nafld-ca","tag-nash-ca","tag-ovari-poliquistic"],"_links":{"self":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts\/14414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/comments?post=14414"}],"version-history":[{"count":0,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts\/14414\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/media\/14417"}],"wp:attachment":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/media?parent=14414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/categories?post=14414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/tags?post=14414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}